Skip to content
The Policy VaultThe Policy Vault

Ojjaara (momelotinib) — United Healthcare

accelerated/blast phase myeloproliferative neoplasms

Initial criteria

  • Patient is less than 19 years of age

Reauthorization criteria

  • Continuation per age-based provision

Approval duration

12 months